Oxbryta is the first-of-its-kind tablet that treats sickle cell in a different way—by working directly on hemoglobin S to interfere with the sickling process (polymerization).Learn more
OXBRYTA is a prescription medicine used for the treatment of sickle cell disease in adults and children 12 years of age and older.
It is not known if OXBRYTA is safe and effective in children below 12 years of age.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Do not take OXBRYTA if you have had an allergic reaction to voxelotor or any of the ingredients in OXBRYTA. See the end of the patient leaflet for a list of the ingredients in OXBRYTA.
If you are receiving exchange transfusions, talk to your healthcare provider about possible difficulties with the interpretation of certain blood tests when taking OXBRYTA.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how OXBRYTA works. OXBRYTA may also affect how other medicines work.
Serious allergic reactions. Tell your healthcare provider or get emergency medical help right away if you get:
These are not all the possible side effects of OXBRYTA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).Keep OXBRYTA and all medicines out of the reach of children.
Oxbryta is a registered trademark of Global Blood Therapeutics, Inc. All other trademarks, registered or unregistered, are the property of their respective owners.
© 2020 Global Blood Therapeutics, Inc. All Rights Reserved. P-VOX-US-00098 v2
This site is intended for US residents only.MORE